MDPI and ACS Style
Majala, S.; Vesterinen, T.; Seppänen, H.; Mustonen, H.; Sundström, J.; Schalin-Jäntti, C.; Gullichsen, R.; Schildt, J.; Kemppainen, J.; Arola, J.;
et al. Correlation of Somatostatin Receptor 1–5 Expression, [68Ga]Ga-DOTANOC, [18F]F-FDG PET/CT and Clinical Outcome in a Prospective Cohort of Pancreatic Neuroendocrine Neoplasms. Cancers 2022, 14, 162.
https://doi.org/10.3390/cancers14010162
AMA Style
Majala S, Vesterinen T, Seppänen H, Mustonen H, Sundström J, Schalin-Jäntti C, Gullichsen R, Schildt J, Kemppainen J, Arola J,
et al. Correlation of Somatostatin Receptor 1–5 Expression, [68Ga]Ga-DOTANOC, [18F]F-FDG PET/CT and Clinical Outcome in a Prospective Cohort of Pancreatic Neuroendocrine Neoplasms. Cancers. 2022; 14(1):162.
https://doi.org/10.3390/cancers14010162
Chicago/Turabian Style
Majala, Susanna, Tiina Vesterinen, Hanna Seppänen, Harri Mustonen, Jari Sundström, Camilla Schalin-Jäntti, Risto Gullichsen, Jukka Schildt, Jukka Kemppainen, Johanna Arola,
and et al. 2022. "Correlation of Somatostatin Receptor 1–5 Expression, [68Ga]Ga-DOTANOC, [18F]F-FDG PET/CT and Clinical Outcome in a Prospective Cohort of Pancreatic Neuroendocrine Neoplasms" Cancers 14, no. 1: 162.
https://doi.org/10.3390/cancers14010162